Nikhil Munshi’s lab at the Dana-Farber Cancer Institute has accumulated an overwhelming amount of data — over a thousand terabytes of intel on healthy cells and cancer cells that could help researchers unlock new secrets about health and disease — what he called the ‘unbelievable complexity of how cells remain normal and become abnormal.’
‘It’s very, very exciting. We can do things we could not do literally two years ago or five years ago. A petabyte of data sounds like a Star Trek number, but a lot of people have [more],’ Munshi, an oncology researcher, said. There’s just one problem: ‘There’s so much demand for informatics, the supply is not there yet. There really is a shortage of good bioinformaticians.’ Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. This name will appear with your comment
https://www.statnews.com/2021/11/19/data-science-biotech-pharma-research/
